Knee pain
Also known as: Pain, Ache, Hurt, Cramp
Methodology & AI Transparency ⓘ
Knee pain Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Knee pain (also termed Pain or Ache) (ICD-10-CM M25.569), Osteoarthritis, Gout & Joint Pain protocols prioritize synovial fluid crystal/cell in Knee pain (M25.569: analysis when effused) paired with baseline and interval Serum Uric Acid in Knee pain (M25.569: (Gout Target)) assessment.
- 2 Real-world patient consensus: Mapped to Osteoarthritis, Gout & Joint Pain under ICD-10-CM M25.569 for Knee pain clinical workups.
- 3 Typical cash cost range: Primary evaluation for Knee pain incorporates synovial fluid crystal/cell in Knee pain (M25.569: analysis when effused) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Knee pain: maintaining Serum Uric Acid in Knee pain (M25.569: (Gout Target)) within < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.569).
Ask our AI Specialists anything about Knee pain
What Is Knee pain?
For patients presenting with Knee pain (also termed Pain or Ache) (ICD-10-CM M25.569), Osteoarthritis, Gout & Joint Pain protocols prioritize synovial fluid crystal/cell in Knee pain (M25.569: analysis when effused) paired with baseline and interval Serum Uric Acid in Knee pain (M25.569: (Gout Target)) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Knee pain (code M25.569) is articular hyaline cartilage in Knee pain (M25.569: proteoglycan degradation), which Osteoarthritis, Gout & Joint Pain clinicians address while surveilling Serum Uric Acid in Knee pain (M25.569: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.569)).
Common Symptoms & Clinical Signs
- • Presentation of Knee pain (M25.569): sudden, intensely painful, in Knee pain (M25.569: red swollen big-toe)
- • Secondary Knee pain clinical sign: localized tendon or in Knee pain (M25.569: bursa tenderness limiting)
- • Symptom flares in Knee pain correlating with Serum Uric Acid in Knee pain (M25.569: (Gout Target)) deviation outside < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.569)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Knee pain (M25.569: analysis when effused) evaluation (M25.569)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Knee pain Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M25.569 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Uric Acid in Knee pain (M25.569: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.569) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Knee pain (M25.569: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M25.569) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Knee pain M25.569] | Preserved joint-space width (M25.569) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Knee pain
Treatment selection for Knee pain depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Knee pain)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Exercise Type and Duration on Pain, Function, and Quality of Life in Patients: What a 3,808-Participant Study Found J Orthop Sports Phys Ther 2026;56(11):724-734. The Journal of orthopaedic and sports physical therapy • 2026-11-15 • Meta-Analysis | N = 3,808 | 94/100 | PMID 42966901 ↗ |
| New Insights on A Phase 3, 28-week, multicentre, randomised, gold-standard blind, compared: What a 498-Participant Study Found LOR was well tolerated despite not meeting the primary endpoint. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 498 | 93/100 | PMID 39808288 ↗ |
| New Insights on A Phase 3, 56-week, randomised, gold-standard blind, compared against a dummy: What a 513-Participant Study Found 513 patients were randomised. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 513 | 93/100 | PMID 39808286 ↗ |
| New Insights on A single intra-articular injection of JTA-004, a combination of human plasma,: What a 746-Participant Study Found A single IA injection of JTA-004 was not superior to a saline solution (LSmean difference: -1.50 mm, 95%CI 5.12; 2.12, p= 0.42) or Synvisc-One® (LSmean difference: 2.40, 95% CI: -1.22; 6.02, p=0.20) for the treatment of OA... Osteoarthritis and cartilage • 2026-02-15 • Phase III Randomized Trial | N = 746 | 93/100 | PMID 41015076 ↗ |
| New Insights on Efficacy of duloxetine for multisite pain in patients with knee pain due to: What a 353-Participant Study Found These results are consistent with duloxetine enhancing the activity of descending inhibitory pain pathways that are dysfunctional in patients with central sensitization and multisite pain. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association • 2021-01-15 • Phase III Randomized Trial | N = 353 | 93/100 | PMID 32245696 ↗ |
Knee pain Patient Community & “People Like Me” Threads
Filter Knee pain community threads and patient logs by age, biological sex, dosage, and treatment duration.